Krystal BiotechFRA:4KB +3.23%58 Current Ratio is 9.46 as of Mar. 2026, which is 47% below its 10-year median of 17.80. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €262.63 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, Krystal Biotech ranks better than 76.2% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Krystal Biotech's current ratio for the quarter that ended in Mar. 2026 was 9.46.
Krystal Biotech has a current ratio of 9.46. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Krystal Biotech's Current Ratio or its related term are showing as below:
FRA:4KB'
s Current Ratio Range Over the Past 10 Years
Min: 6.73 Med: 17.8 Max: 105.46
Current: 9.46
During the past 10 years, Krystal Biotech's highest Current Ratio was 105.46. The lowest was 6.73. And the median was 17.80.
FRA:4KB's Current Ratio is ranked better than 76.2% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs FRA:4KB: 9.46
Krystal Biotech (FRA:4KB) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Krystal Biotech Current Ratio Related Terms
Krystal Biotech Current Ratio Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4KB vs NUVL, PRAX, TECH: Current Ratio Comparison
For the Biotechnology subindustry, Krystal Biotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's Current Ratio distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech (FRA:4KB) has a Current Ratio of 9.46 as of Mar. 2026. This is 47% below median its historical median of 17.80. Over the past decade, Krystal Biotech's Current Ratio has ranged from 6.73 to 105.46. According to the industry distribution chart, Krystal Biotech ranks #337 out of 1416 companies in the Biotechnology industry, placing it in the top 23.8%.
Is Krystal Biotech's Current Ratio too high?
Krystal Biotech's current Current Ratio of 9.46 is 47% below median its 10-year median of 17.80. Over the past 10 years, this metric has ranged from a low of 6.73 to a high of 105.46. The Biotechnology industry median Current Ratio is 3.89. Krystal Biotech's value of 9.46 is 143.5% above this industry median. Based on the distribution chart, Krystal Biotech ranks #337 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Current Ratio compare to NUVL and PRAX?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #337 out of 1416 companies for Current Ratio. This places Krystal Biotech in the top 24% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Krystal Biotech's value of 9.46 is 143.5% above this benchmark. Historically, Krystal Biotech's own Current Ratio has ranged from 6.73 to 105.46 over the past decade. While the company's 10-year median is 17.80 vs. the industry median of 3.89, Krystal Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krystal Biotech's current Current Ratio of 9.46 is 143.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krystal Biotech's current Current Ratio is 9.46, which is 47% below median its own 10-year median of 17.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €262.63, compared to a current price of €313.40 — trading 19.3% above its estimated fair value. The current Current Ratio is 9.46, which is 47% below median its 10-year median of 17.80 and 143.5% above the Biotechnology industry median of 3.89. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Current Ratio is 9.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €313.40 is trading 19.3% above its estimated GF Value™ of €262.63.
GuruFocus considers Krystal Biotech to be Modestly Overvalued.
Key valuation signals for FRA:4KB:
Current Ratio: 9.46 (47% below median its 10-year median of 17.80)
GF Value™: €262.63 vs. price of €313.40 (19.3% above fair value)
Industry Position: 143.5% above the Biotechnology median (#337 of 1416)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score
Get the complete analysis for FRA:4KB
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
